HIGHLIGHTS
- who: Piroska Klement from the Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carlu2011Neuberg Str1, Hannover, Germany have published the research work: Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy, in the Journal: (JOURNAL)
- what: The authors show an interesting long-term course of a patient who relapsed after allogeneic stem cell transplantation (alloHCT) with SF3B1- and SRSF2-mutated AML and received selinexor as maintenance treatment for 4 years.
- how: The authors analyzed the clonal response patterns of 15 patients with relapsed/refractory AML . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.